$2.8 B

AERI Mkt cap, 22-Jun-2018
Aerie Pharmaceuticals Net income (FY, 2017)-145.1 M
Aerie Pharmaceuticals EBIT (FY, 2017)-145.7 M
Aerie Pharmaceuticals Cash, 31-Dec-2017197.6 M

Aerie Pharmaceuticals Financials

Aerie Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

52.4 m72.1 m

General and administrative expense

44.5 m73.6 m

Operating expense total

96.9 m145.7 m

EBIT

(96.9 m)(145.7 m)

Pre tax profit

(98.9 m)(146.9 m)

Income tax expense

(193 k)(1.8 m)

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)(145.1 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

R&D expense

10.6 m9.9 m12.3 m13.3 m12.7 m

General and administrative expense

7.5 m7.5 m9.8 m9.4 m10.6 m

Operating expense total

18.1 m17.4 m22.1 m22.7 m23.3 m

EBIT

(18.1 m)(17.4 m)(22.1 m)(22.7 m)(23.3 m)

Pre tax profit

(18.6 m)(17.9 m)(22.7 m)(23.2 m)(23.8 m)

Income tax expense

(152 k)(72 k)(46 k)(47 k)(39 k)

Net Income

(18.5 m)(31.6 m)(17.2 m)(18.8 m)(18 m)(22.7 m)(23.2 m)(23.8 m)

Aerie Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

69.6 m85.6 m91.1 m197.9 m197.6 m

Accounts Receivable

399 m

Inventories

618 k1.1 m1.9 m4 m

Current Assets

70.3 m141 m138.4 m237.7 m254.1 m

PP&E

31.9 m

Total Assets

70.5 m161.1 m159.1 m248.3 m290.3 m

Accounts Payable

3.5 m551 k551 k551 k6.2 m

Current Liabilities

3.5 m8.9 m17.1 m19.4 m25.2 m

Total Liabilities

142.9 m154.7 m

Additional Paid-in Capital

162 m171.3 m236.5 m422 m597.3 m

Retained Earnings

(143.2 m)(217.6 m)(316.6 m)(461.7 m)

Total Equity

67 m18.8 m105.3 m135.6 m

Financial Leverage

1.1 x8.5 x2.4 x2.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

4.6 m35.8 m27.9 m148.9 m113.5 m100.9 m106.9 m74.3 m58.5 m211.9 m

Current Assets

7.1 m65.8 m57.3 m171.7 m171 m159.9 m156.6 m120.7 m108.2 m256.5 m

Total Assets

7.2 m66 m57.7 m173.3 m195.2 m176.3 m175.2 m139.2 m120.1 m265.9 m

Accounts Payable

3.2 m3.7 m4.8 m7 m21.9 m17.7 m18 m15.5 m13.6 m13.5 m

Current Liabilities

18.1 m3.7 m4.8 m7 m22.4 m18.3 m18.5 m16 m14.1 m14.1 m

Total Liabilities

29.6 m3.7 m4.8 m131.1 m146.6 m142.5 m142.8 m139.4 m137.5 m137.6 m

Additional Paid-in Capital

1.1 m164 m166.4 m168.8 m209.1 m213.1 m229.7 m240.2 m246.1 m415.6 m

Retained Earnings

(160.4 m)(179.2 m)(197.2 m)(240.3 m)(263.5 m)(287.3 m)

Total Equity

(83.7 m)62.3 m52.9 m42.2 m33.9 m32.5 m128.4 m

Financial Leverage

-0.1 x1.1 x1.1 x4.1 x5.2 x5.4 x2.1 x

Aerie Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)(145.1 m)

Depreciation and Amortization

64 k73 k252 k970 k1.4 m

Accounts Payable

2 m551 k

Cash From Operating Activities

(16.4 m)(33.7 m)(55.7 m)(79.8 m)(93.2 m)

Cash From Investing Activities

(63 k)(73.3 m)9.4 m18.1 m(42.8 m)

Cash From Financing Activities

83.2 m123 m51.8 m168.6 m135.6 m

Interest Paid

2.2 m2.2 m2.2 m

Income Taxes Paid

600 k1.8 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(20.9 m)(6.7 m)(18.5 m)(31.6 m)(17.2 m)(36 m)(54 m)(22.7 m)(45.9 m)(69.7 m)

Depreciation and Amortization

47 k15 k31 k50 k24 k60 k102 k223 k457 k702 k

Accounts Payable

1 m208 k1.4 m2.3 m(12 k)(6 k)2.4 m(6 k)(6 k)

Cash From Operating Activities

(11.6 m)(4.5 m)(12.9 m)(22.4 m)(13.3 m)(29.6 m)(41.5 m)(19.4 m)(39.8 m)(61 m)

Cash From Investing Activities

(28 k)(29.4 m)(28.9 m)(22.6 m)6.1 m9.3 m14.4 m2.4 m5.1 m14 m

Cash From Financing Activities

13.3 m65 k74 k124.2 m35.1 m35.6 m48.5 m128 k2.2 m167.9 m

Interest Paid

551 k1.1 m1.6 m551 k1.1 m1.6 m

Income Taxes Paid

469 k600 k1.8 m1.8 m1.8 m

Aerie Pharmaceuticals Ratios

USDY, 2017

Financial Leverage

2.1 x
Report incorrect company information